Inge Christoffer Olsen

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

Espen A. Haavardsholm, Anna‐Birgitte Aga, Inge Christoffer Olsen et al. · BMJ · 2016 · 283 citations · Full text

Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial

Håvard Ove Skjerven, Eva Maria Rehbinder, Riyas Vettukattil et al. · The Lancet · 2020 · 229 citations

Nutrition, Allergy, Skin Emollient +15

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010

Anna‐Birgitte Aga, Elisabeth Lie, Till Uhlig et al. · Annals of the Rheumatic Diseases · 2013 · 175 citations · Full text

Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial

Håvard Ove Skjerven, Anine Lie, Riyas Vettukattil et al. · The Lancet · 2022 · 157 citations

Nutrition, Food Allergy, Allergy Medicine +16